Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ILMN illumina.com
Illumina develops, manufactures and sells DNA sequencing and array-based genomic technologies. Its customers are in the research, clinical and applied markets, and its products are used in life sciences, oncology, reproductive health, agriculture and other emerging segments. Revenue comes from products, including sequencing instruments such as the NovaSeq X and recurring consumables, and from services and other offerings. The company has expanded into proteomics through its SomaLogic acquisition. It reports a rest-of-world organic growth metric that excludes Greater China, reflecting its inclusion on China's Unreliable Entities List. Strategically, Illumina is focused on broadening its sequencing ecosystem and enabling AI-driven analysis of human biology. Updated
Three new names are entering the S&P 500, swapping out brewers and homebuilders for fuel-cell technology and genomics, but whether that trade actually benefits VOO holders depends on a math problem most…
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Pre-Market Stock Futures: Futures are trading sharply lower as we get set to end one of the most exciting weeks on Wall Street in 25 years. Positive meetings in China with President…
Pre-Market Stock Futures: Futures are trading higher on Thursday after another wild day on Wall Street, during which the major indices moved in different directions. Another round of disturbing inflation data hit…
What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible? The personalized biotech…
The Rise of a Frenzied Trading Style Cathie Wood, founder of ARK Invest, burst into investor consciousness in 2020 when her flagship ARK Innovation ETF (NYSEARCA:ARKK) soared 153%, fueled by bold bets…
It’s always a good idea to pay attention to insider buying. After all, it’s the insiders who know their company the best. And if they’re willing to put their money where their…
Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4. As usual, there were many moves into and out of the investment…
Live Updates Nasdaq Now Up 1.2% 1:30pm ETEric BleekerAs of 1:30 p.m. ET, the Nasdaq-100 is up 1.25%. That’s significantly outpacing the S&P 500’s .53% gain. The Dow Jones is down very…
Insider buying slowed ahead of the third-quarter earnings reporting season, but an IPO tempted one insider, and a repeat buyer returned to boost a stake.
Stock spinoffs are a popular corporate strategy for unlocking shareholder value, but one that rarely pays off for investors. Harvard Business Review found half of all spinoffs failed to create any new…
Monday's top analyst upgrades and downgrades included Arm, General Electric, Micron Technology and Salesforce.
Friday's top analyst upgrades and downgrades included Agilent, Boeing, General Electric, Lockheed Martin, Meta Platforms, Micron Technology, Redfin, Salesforce, Trade Desk, Unity Software and Workday.
Shares of regional banks took a beating on Monday, but, having survived the day, appeared to be making a partial recovery in premarket trading on Tuesday.
January consumer price index data is due out before markets open on Tuesday. Here's what to watch for.
Illumina develops, manufactures and sells DNA sequencing and array-based genomic technologies. Its customers are in the research, clinical and applied markets, and its products are used in life sciences, oncology, reproductive health, agriculture and other emerging segments.
24/7 Wall St.'s 12-month price target for ILMN is $281.82, rated Buy. The Wall Street consensus target is $261.60. ILMN price prediction →
